PWPS
NBIX icon

Pinnacle Wealth Planning Services’s Neurocrine Biosciences NBIX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.93K Buy
53
+2
+4% +$297 ﹤0.01% 2112
2026
Q1 		$6.72K Buy
51
+3
+6% +$398 ﹤0.01% 2163
2025
Q4 		$6.81K Buy
+48
New +$6.95K ﹤0.01% 2179
2021
Q1 		– Sell
-26
Closed -$2K – 1366
2020
Q4 		$2K Buy
+26
New +$2.51K ﹤0.01% 1953

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pinnacle Wealth Planning Services's NBIX Position: Q2 2026 in Review

Pinnacle Wealth Planning Services increased its Neurocrine Biosciences (NBIX) stake by 3.9% in Q2 2026, buying an estimated $297 and bringing the position to 53 shares worth $8.93K. The position accounts for ﹤0.01% of the portfolio, ranked #2112.

Pinnacle Wealth Planning Services first reported a position in NBIX in Q4 2020 and has held it in 4 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Pinnacle Wealth Planning Services held 53 shares of Neurocrine Biosciences worth $8.93K as of Q2 2026.
  • Pinnacle Wealth Planning Services bought 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #2112 holding.
  • Pinnacle Wealth Planning Services first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 4 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.